Physician profile
Laura J Hunter
NPI 1578520540
$3,138.07
in general payments reported to CMS, 2019-2025
34 companies · $18.25 in 2025
The $18.25 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $1,138 · 2021: $977 · 2022: $52.59 · 2025: $18.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $481.83 | 2019-2021 | |
| Novo Nordisk INC | $385.47 | 2019-2021 | |
| Amgen INC. | $306.63 | 2019-2025 | Repatha, Otezla |
| Abbvie INC. | $279.32 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $235.43 | 2019-2021 | |
| Glaxosmithkline, LLC. | $158.42 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.82 | 2019-2021 | |
| Irhythm Technologies, INC. | $110.69 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $109.14 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $76.74 | 2019-2020 | |
| Pfizer INC. | $72.58 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $69.95 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.63 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $63.39 | 2021 | |
| Novartis Pharmaceuticals Corporation | $56.42 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $49.30 | 2019-2021 | |
| Allergan, INC. | $48.82 | 2020 | |
| Janssen Pharmaceuticals, INC | $44.79 | 2019 | |
| Shire North American Group INC | $42.64 | 2019 | |
| Merck Sharp & Dohme LLC | $40.63 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $38.77 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $37.56 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $36.23 | 2020 | |
| Genentech USA, INC. | $35.33 | 2019 | |
| Abbott Laboratories | $29.82 | 2019-2021 | |
| Astellas Pharma US INC | $29.03 | 2019-2021 | |
| Mannkind Corporation | $15.42 | 2020 | |
| Nestle Healthcare Nutrition INC. | $14.99 | 2021 | |
| Currax Pharmaceuticals LLC | $14.96 | 2021 | |
| Ironshore Pharmaceuticals INC. | $14.70 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.10 | 2021 | |
| Jazz Pharmaceuticals INC. | $12.28 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.15 | 2019 | |
| Amneal Pharmaceuticals LLC | $12.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.